⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968809 | 0.82 | — | — | |
| SCHEMBL7056812 | 0.75 | — | — | |
| SCHEMBL8031023 | 0.73 | — | — | |
| SCHEMBL13437897 | 0.71 | — | — | |
| SCHEMBL2686581 | 0.69 | — | — | |
| SCHEMBL10795138 | 0.69 | — | — | |
| SCHEMBL8763793 | 0.67 | TSHR (0.33) | — | |
| SCHEMBL20189041 | 0.67 | — | — | |
| SCHEMBL15863920 | 0.65 | — | — | |
| SCHEMBL3627555 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-5972937-A | Heterocyclic compounds possessing 5HT2C receptor antagonist activity | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-10-26 | — | — | US | disclosed |
| EP-0807104-A2 | HETEROCYCLIC COMPOUNDS POSSESSING 5HT 2C? RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996023769-A2 | HETEROCYCLIC COMPOUNDS POSSESSING 5HT2C RECEPTOR ANTAGONIST ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |